The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
A Molecular Signature to Discriminate Dysplastic Nodules From Early Hepatocellular Carcinoma in HCV Cirrhosis
Open accessAbstract
BACKGROUND & AIMS: Small liver nodules approximately 2 cm are difficult to characterize by radiologic or pathologic examination. Our aim was to identify a molecular signature to diagnose early hepatocellular carcinoma (HCC). METHODS: The transcriptional profiles of 55 candidate genes were assessed by quantitative real-time reverse-transcription polymerase chain reaction (RT-PCR) in 17 dysplastic nodules (diameter, 10 mm) and 20 early HCC (diameter, 18 mm) from HCV cirrhotic patients undergoing resection/transplantation and 10 nontumoral cirrhotic tissues and 10 normal liver tissues. Candidate genes were confirmed by quantitative RT-PCR in 20 advanced HCCs and by immunohistochemistry in 75 samples and validated in an independent set of 29 samples (dysplastic nodules [10] and small HCC [19; diameter, 20 mm]). RESULTS: Twelve genes were significantly, differentially expressed in early HCCs compared with dysplastic nodules (>2-fold change; area under the receiver operating characteristic curve > or =0.8): this included TERT, GPC3, gankyrin, survivin, TOP2A, LYVE1, E-cadherin, IGFBP3, PDGFRA, TGFA, cyclin D1, and HGF. Logistic regression analysis identified a 3-gene set including GPC3 (18-fold increase in HCC, P = .01), LYVE1 (12-fold decrease in HCC, P = .0001), and survivin (2.2-fold increase in HCC, P = .02), which had a discriminative accuracy of 94%. The validity of the gene signature was confirmed in a prospective testing set. GPC3 immunostaining was positive in all HCCs and negative in dysplastic nodules (22/22 vs 0/14, respectively, P < .001). Nuclear staining for survivin was positive in 12 of 13 advanced HCC cases and in 1 of 9 early tumors. CONCLUSIONS: Molecular data based on gene transcriptional profiles of a 3-gene set allow a reliable diagnosis of early HCC. Immunostaining of GPC3 confirms the diagnosis of HCC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Management of Hepatocellular Carcinoma *
Bruix, J., & Sherman, M. (2005) · Hepatology · doi:10.1002/hep.20933 · Cited by 5,857
Self-citationTM4: a free, open-source system for microarray data management and analysis
Saeed, A. I., Sharov, V., White, J., Li, J., Liang, W., Bhagabati, N., Braisted, J., Klapa, M., Currier, T., Thiagarajan, M., et al. (2003) · BioTechniques · doi:10.2144/03342mt01 · Cited by 4,837
Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference
Bruix, J., Sherman, M., Llovet, J. M., Beaugrand, M., Lencioni, R., Burroughs, A. K., Christensen, E., Pagliaro, L., Colombo, M., & Rodés, J. (2001) · Journal of Hepatology · doi:10.1016/s0168-8278(01)00130-1 · Cited by 4,089
Self-citationLlovet, J. M., Burroughs, A., & Bruix, J. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14964-1 · Cited by 3,608
Self-citationPrimary liver cancer: Worldwide incidence and trends
Bosch, F. X., Ribes, J., Díaz, M., & Cléries, R. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.09.011 · Cited by 2,477
Terminology of nodular hepatocellular lesions
Wanless, I. R. (1995) · Hepatology · doi:10.1002/hep.1840220341 · Cited by 1,130
Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma
Capurro, M., Wanless, I. R., Sherman, M., Deboer, G., Shi, W., Miyoshi, E., & Filmus, J. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00689-9 · Cited by 917
Prediction of Survival in Diffuse Large-B-Cell Lymphoma Based on the Expression of Six Genes
Lossos, I. S., Czerwinski, D. K., Alizadeh, A. A., Wechser, M. A., Tibshirani, R., Botstein, D., & Levy, R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032520 · Cited by 911
Resection and Liver Transplantation for Hepatocellular Carcinoma
Llovet, J. M., Schwartz, M., & Mazzaferro, V. (2005) · Seminars in Liver Disease · doi:10.1055/s-2005-871198 · Cited by 879
Self-citationBolondi, L., Sofia, S., Siringo, S., Gaiani, S., Casali, A., Zironi, G., Piscaglia, F., Gramantieri, L., Zanetti, M., & Sherman, M. (2001) · Gut · doi:10.1136/gut.48.2.251 · Cited by 643
Sangiovanni, A., Del Ninno, E., Fasani, P., De Fazio, C., Ronchi, G., Romeo, R., Morabito, A., de Franchis, R., & Colombo, M. (2004) · Gastroenterology · doi:10.1053/j.gastro.2003.12.049 · Cited by 600
Glypican-3 Promotes the Growth of Hepatocellular Carcinoma by Stimulating Canonical Wnt Signaling
Capurro, M. I., Xiang, Y.-Y., Lobe, C., & Filmus, J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4244 · Cited by 469
Ikai, I., Arii, S., Kojiro, M., Ichida, T., Makuuchi, M., Matsuyama, Y., Nakanuma, Y., Okita, K., Omata, M., Takayasu, K., et al. (2004) · Cancer · doi:10.1002/cncr.20426 · Cited by 451
Bolondi, L., Gaiani, S., Celli, N., Golfieri, R., Grigioni, W. F., Leoni, S., Venturi, A. M., & Piscaglia, F. (2005) · Hepatology · doi:10.1002/hep.20728 · Cited by 451
Burrel, M., Llovet, J. M., Ayuso, C., Iglesias, C., Sala, M., Miquel, R., Caralt, T., Ayuso, J. R., Solé, M., Sanchez, M., et al. (2003) · Hepatology · doi:10.1002/hep.1840380430 · Cited by 451
Self-citationCarreira, C. M., Nasser, S. M., di Tomaso, E., Padera, T. P., Boucher, Y., Tomarev, S. I., & Jain, R. K. (2001) · PubMed · Cited by 444
Glypican-3 as a Serum Marker for Hepatocellular Carcinoma
Capurro, M., & Filmus, J. (2005) · Cancer Research · doi:10.1158/0008-5472.372.65.1 · Cited by 432
Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker
Nakatsura, T., Yoshitake, Y., Senju, S., Monji, M., Komori, H., Motomura, Y., Hosaka, S., Beppu, T., Ishiko, T., Kamohara, H., et al. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(03)00908-2 · Cited by 430
The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma
Yamauchi, N., Watanabe, A., Hishinuma, M., Ohashi, K.-I., Midorikawa, Y., Morishita, Y., Niki, T., Shibahara, J., Mori, M., Makuuchi, M., et al. (2005) · Modern Pathology · doi:10.1038/modpathol.3800436 · Cited by 338
Survivin promotes cell proliferation in human hepatocellular carcinoma
Ito, T., Shiraki, K., Sugimoto, K., Yamanaka, T., Fujikawa, K., Ito, M., Takase, K., Moriyama, M., Kawano, H., Hayashida, M., et al. (2000) · Hepatology · doi:10.1053/he.2000.6496 · Cited by 329
Hippo, Y., Watanabe, K., Watanabe, A., Midorikawa, Y., Yamamoto, S., Ihara, S., Tokita, S., Iwanari, H., Ito, Y., Nakano, K., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2191 · Cited by 297
Chuma, M., Sakamoto, M., Yamazaki, K., Ohta, T., Ohki, M., Asaka, M., & Hirohashi, S. (2003) · Hepatology · doi:10.1053/jhep.2003.50022 · Cited by 294
Zhu, Z.-W., Friess, H., Wang, L., Abou-Shady, M., Zimmermann, A., Lander, A. D., Korc, M., Kleeff, J., & Büchler, M. W. (2001) · Gut · doi:10.1136/gut.48.4.558 · Cited by 291
Neoangiogenesis and Sinusoidal "Capillarization" in Dysplastic Nodules of the Liver
Park, Y. N., Yang, C.-P., Fernandez, G. J., Cubukcu, O., Thung, S. N., & Theise, N. D. (1998) · The American Journal of Surgical Pathology · doi:10.1097/00000478-199806000-00002 · Cited by 285
Self-citation(1997) · PubMed · Cited by 239
Paradis, V., Degos, F., Dargère, D., Pham, N., Belghiti, J., Degott, C., Janeau, J.-L., Bezeaud, A., Delforge, D., Cubizolles, M., et al. (2005) · Hepatology · doi:10.1002/hep.20505 · Cited by 220
Borzio, M., Fargion, S., Borzio, F., Fracanzani, A. L., Croce, A. M., Stroffolini, T., Oldani, S., Cotichini, R., & Roncalli, M. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(03)00190-9 · Cited by 199
Absence of lymphangiogenesis and intratumoural lymph vessels in human metastatic breast cancer
Williams, C. S., Leek, R. D., Robson, A. M., Banerji, S., Prevo, R., Harris, A. L., & Jackson, D. G. (2003) · The Journal of Pathology · doi:10.1002/path.1343 · Cited by 198
Selection of appropriate control genes to assess expression of tumor antigens using real-time RT-PCR
Aerts, J. L., Gonzales, M. I., & Topalian, S. L. (2004) · BioTechniques · doi:10.2144/04361st04 · Cited by 177
Newer markers for hepatocellular carcinoma
Marrero, J. A., & Lok, A. S. F. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.09.024 · Cited by 175
Focus on dysplastic nodules and early hepatocellular carcinoma: An Eastern point of view
Kojiro, M. (2004) · Liver Transplantation · doi:10.1002/lt.20042 · Cited by 171
Nam, S. W., Park, J. Y., Ramasamy, A., Shevade, S., Islam, A., Long, P. M., Park, C. K., Park, S. E., Kim, S. Y., Lee, S. H., et al. (2005) · Hepatology · doi:10.1002/hep.20878 · Cited by 167
Telomeres and telomerase: A dual role in hepatocarcinogenesis
Satyanarayana, A., Manns, M. P., & Rudolph, L. K. (2004) · Hepatology · doi:10.1002/hep.20308 · Cited by 158
Identification of novel tumor markers in hepatitis C virus-associated hepatocellular carcinoma.
Smith, M. W., Yue, Z. N., Geiss, G. K., Sadovnikova, N. Y., Carter, V. S., Boix, L., Lázaro, C. A., Rosenberg, G. B., Bumgarner, R. E., Fausto, N., et al. (2003) · PubMed · Cited by 148
Self-citationTerasaki, S., Kaneko, S., Kobayashi, K., Nonomura, A., & Nakanuma, Y. (1998) · Gastroenterology · doi:10.1016/s0016-5085(98)70093-9 · Cited by 118
Molecular Profiling of Hepatocellular Carcinomas (HCC) Using a Large-Scale Real-Time RT-PCR Approach
Paradis, V., Bièche, I., Dargère, D., et al. (2003) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63700-5 · Cited by 89
Morphological Changes of Early Human Hepatocarcinogenesis
Hytiroglou, P. (2004) · Seminars in Liver Disease · doi:10.1055/s-2004-823097 · Cited by 80
Miura, N., Maeda, Y., Kanbe, T., Yazama, H., Takeda, Y., Sato, R., Tsukamoto, T., Sato, E., Marumoto, A., Harada, T., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1487 · Cited by 77
Colombat, M., Paradis, V., Bièche, I., Dargère, D., Laurendeau, I., Belghiti, J., Vidaud, M., Degott, C., & Bédossa, P. (2003) · The Journal of Pathology · doi:10.1002/path.1451 · Cited by 34
Cited by
Hepatocellular Carcinoma: Epidemiology and Molecular Carcinogenesis
El–Serag, H. B., & Rudolph, K. L. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.04.061 · Cited by 5,415
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
European Association for the Study of the Liver, & European Organisation for Research and Treatment of Cancer (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.12.001 · Cited by 5,218
“The performance of this signature was externally validated in a different set of samples [118,119].”
BackgroundForner, A., Llovet, J. M., & Bruix, J. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61347-0 · Cited by 4,022
Self-citationEl-Serag, H. B. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1001683 · Cited by 3,529
Llovet, J. M., Zucman-Rossi, J., Pikarsky, E., Sangro, B., Schwartz, M., Sherman, M., & Gores, G. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.18 · Cited by 2,531
Self-citation
Metadata
- Authors
- Llovet, J. M., Chen, Y., Wurmbach, E., Roayaie, S., Fiel, M. I., Schwartz, M., Thung, S. N., Khitrov, G., Zhang, W., Villanueva, A., Battiston, C., Mazzaferro, V., Bruix, J., Waxman, S., & Friedman, S. L.
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2006-12
- Volume
- 131
- Issue
- 6
- Pages
- 1758-1767
- ISSN
- 0016-5085 (ISSN-L)
- OpenAlex
- W2065589690
- Cited by
- 386
- References
- 39
- FWCI
- 20.90
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.